Literature DB >> 3128309

Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer.

E Andersen1, H Pedersen.   

Abstract

The toxicities of oral Ftorafur (1 g/m2/day 1-21) and intravenous 5-fluorouracil (5-FU) (500 mg/m2/day 1-5) were compared in a prospective randomized study in patients with colorectal cancer. The treatment courses were repeated every 6th week. Leucopenia was more common after 5-FU. Leucocyte nadir in connection with first treatment cycle was on average seen on day 15 in patients receiving 5-FU and on day 28 in patients receiving Ftorafur. Significantly more patients on 5-FU developed stomatitis. There was no difference in the number of patients with diarrhea or nausea/vomiting. Median survival and response rates were not significantly different after the two treatment schedules.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3128309     DOI: 10.3109/02841868709113713

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

Review 1.  Interventions for preventing oral mucositis for patients with cancer receiving treatment.

Authors:  Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation.

Authors:  F A Calvo; A Aldaz; L Zufía; D de la Mata; J Serrano; R García; J A Arranz; A Alvarado; J Giráldez
Journal:  Clin Transl Oncol       Date:  2006-07       Impact factor: 3.405

3.  5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.

Authors:  D Brohée
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

Review 4.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

Review 5.  Oral versus intravenous fluoropyrimidines for colorectal cancer.

Authors:  Fiona Chionh; David Lau; Yvonne Yeung; Timothy Price; Niall Tebbutt
Journal:  Cochrane Database Syst Rev       Date:  2017-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.